Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11309994 | 0.96 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL776818 | 0.94 | LPAR3 (0.48) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL11315336 | 0.92 | LPAR3 (0.52) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL28056079 | 0.90 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL31519194 | 0.88 | CYP3A4 (0.41) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL27718749 | 0.87 | LPAR3 (0.47) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL779257 | 0.87 | MEN1 (0.35) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL5494226 | 0.83 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL11319528 | 0.82 | CYP3A4 (0.39) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL11311349 | 0.82 | CYP3A4 (0.50) | CYP3A4LPAR3LPAR2LPAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682205-A1 | CURED PRODUCT, CURED PRODUCT-CONTAINING CARBON MATERIAL, NEGATIVE ELECTRODE, AND NONAQUEOUS SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-20260011730-A1 | CURED PRODUCT, CURED PRODUCT-CONTAINING CARBON MATERIAL, NEGATIVE ELECTRODE, AND NONAQUEOUS SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2026-01-08 | — | — | US | disclosed |
| CN-119591768-A | Organic polymer carrier, Z-N catalyst, and preparation method and application thereof | 中国石油天然气股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| CN-110499204-A | Slideway lubricant | AFTON CHEMICAL CORP | 2019-11-26 | — | — | CN | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10333172-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1509537-B1 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-4257987-A | SYNERGISTIC ARTHROPODICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-03-24 | — | — | US | disclosed |
| EP-0012452-A2 | Phosphoric acid esters and their use in pesticidal compositions | BAYER AG (DE) | 1980-06-25 | — | — | EP | disclosed |
| EP-0000127-A1 | Insecticidal and acaricidal compositions, their manufacture and their use | BAYER AG (DE) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260011730-A1 | CURED PRODUCT, CURED PRODUCT-CONTAINING CARBON MATERIAL, NEGATIVE ELECTRODE, AND NONAQUEOUS SECONDARY BATTERY | DNMT3A, TET3, SMCHD1 | CYP3A4 3015/4885LPAR3 4435/4885LPAR2 4329/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | CYP3A4 2660/4885LPAR3 4005/4885LPAR2 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.